Pfizer falls as slowing demand for COVID-19 drugs weighs on outlook

By Geoffrey Smith and Senad Karaahmetovic -- Pfizer (NYSE:PFE) stock fell nearly 3% in premarket on Tuesday after it predicted profit and revenue will fall this year, a reflection of slowing demand for its COVID-19 vaccine and antiviral products.

The pharma giant said it expects adjusted earnings per share to fall to a range of $3.25-$3.45, well below consensus expectations of around $4.44.

For revenue, it expects a range around a midpoint of $69 billion, which also represents a clear shortfall versus forecasts of $74.3B.

In the fourth quarter, Pfizer's adjusted EPS was $1.14, some 5% ahead of the market consensus, while revenue growth slowed to only 2% on the year, at $24.29B.

By 07:05 ET (12:05 GMT), Pfizer stock was down 3.3%, on course for its lowest open in nearly four months.

The shortfalls appeared to be caused at least in part by diverging assumptions about the outlook for COVID-19-related sales in China this year.

Analysts have assumed that demand for the group’s antiviral drug Paxlovid in particular will remain strong, now that China’s relaxation of its quarantine and mobility rules is allowing faster transmission of the disease.

However, Paxlovid is set to be dropped from a list of drugs for which the government will reimburse purchase costs as of March. Chief executive Albert Bourla is on record as saying that he expects to be able to offer the drug outside of state healthcare schemes from April 1, but the group hasn’t budgeted for any Paxlovid sales in China after March.

Pfizer's COVID-19 vaccine Comirnaty was the first to be approved by most world health regulators during the pandemic, and sales for Comirnaty and the later arrival of Paxlovid have come to dominate the group's business, far outstripping demand for its other drugs.

However, with the pandemic having eased and natural immunity to COVID-19 having risen in most of the world, the company is now forecasting a sharp drop in its sales. Revenue from Comirnaty is set to fall by nearly two-thirds to around $13.5B, while revenue from Paxlovid is expected to fall 58% to around $8B.

The windfall from those two drugs allowed Pfizer to pay out $11B in dividends and stock buybacks last year. The company noted that its current financial guidance "does not anticipate any share repurchases in 2023."

BMO analysts said Pfizer's EPS guidance is disappointing, although overall results were "better than it could have been, given the uncertainty around how the company would forecast COVID-19 revenues."

Cantor Fitzgerald analysts weighed in more positively on the results as "the miss on the 2023 guide was widely anticipated, which is why PFE's stock has been weak ahead of earnings." The analysts remain positive on PFE stock going forward and reiterated an Overweight rating and a $75 per share price target.

"We continue to believe that the sales potential of PFE's products and pipeline remain underappreciated in 2025+. Therefore, upwards earnings estimate revisions and multiple expansion, in 2025+, should move PFE's shares higher, in our view."

By 08:55 ET (13:55 GMT), Pfizer stock was down 2.7%.

Begin trading today! Create an account by completing our form

Privacy Notice

At One Financial Markets we are committed to safeguarding your privacy.

Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.

Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.

Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.

By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.7% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Back to top

Office network
  • London Office
    One Financial Markets 

    1 Finsbury Market
    EC2A 2BN
    United Kingdom

    T:  + 44 ( 0 ) 203 857 2000
  • Dubai Office
    One Financial Markets 
    OT19-39 Central Park Tower
    Dubai International Finance Centre
    United Arab Emirates
    T: + 971 44 22 888

One Financial Markets is the trading name of Axi Financial Services (UK) Ltd, a company registered in England with company number 6050593. Axi Financial Services (UK) Ltd is authorised and regulated by the Financial Conduct Authority in the UK (under firm reference number 466201) and the Financial Sector Conduct Authority in South Africa (with FSP number 45784).

The information on this site is not directed at residents of the United States, Belgium, Poland or any particular country outside the UK and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation. is owned and operated by Axi Financial Services (UK) Ltd.

Award winning broker
We have been presented with a number of awards that recognise the quality of our service and dedication to our clients :

Best FSA Regulated Broker
Saudi Money Expo

Best Education Product
Saudi Money Expo

Best Broker - Online Trading
IAIR Awards

Best Institutional Broker
Saudi Money Expo

Best FX Services Broker
CN Forex

Top International
FX Broker 2015

Saudi Money Expo

Broker of the Year
Online Trading – Middle East

IAIR Awards

Best Forex
Customer Service 2018

JFEX Awards

We accept the following payment methods: